Search Results
Sep 30, 2025, 09:30 ET Lung Cancer Research Foundation Announces Recipients of LCRF|Bayer Lung Cancer Research Award
with the potential to extend survival and improve quality of life for people with lung cancer. LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer. To date, LCRF has funded 431 research grants, totaling nearly $49 million,
More news about: Lung Cancer Research Foundation
Sep 30, 2025, 09:00 ET Maxeon Solar Technologies and Hardt Electric Enable the American College of Chest Physicians to Power HQ with Clean Solar Energy
directly supporting CHEST's mission to advance lung health and improve air quality for the Chicagoland community. "The solar installation at CHEST headquarters reflects our continued commitment to social responsibility and to advancing lung health," said Robert Musacchio, PhD, CEO of
More news about: Maxeon Solar Technologies, Ltd.
Sep 30, 2025, 08:30 ET IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and
More news about: IceCure Medical
Sep 30, 2025, 07:11 ET Celebrate National Extra Virgin Olive Oil Day With Gundry MD Polyphenol-Rich Olive Oil: Dr. Steven Gundry Unveils the Life-Changing Benefits of EVOO
Gundry MD, Dr. Steven Gundry was one of the world's top cardiothoracic surgeons Currently, he's the medical director at The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Santa Barbara, California where he's spent the past 25 years helping people restore
More news about: Gundry MD
Sep 30, 2025, 03:30 ET EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
squamous cell carcinoma and other malignancies, and zenocutuzumab, an approved product for patients with NRG1 fusion–driven tumors such as pancreatic and lung cancers. Despite significant advances in oncology, patients with these tumor types continue to face poor prognoses and limited treatment options, underscoring
More news about: EQT
Sep 29, 2025, 17:31 ET DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsight
anti-B7-H3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload. Co-developed with Daiichi Sankyo, it is in Phase III trials for small cell lung cancer (SCLC; NCT06203210) and Phase II trials for breast cancer (NCT06330064). The candidate is also being explored across multiple additional tumor
More news about: DelveInsight Business Research, LLP
Sep 29, 2025, 16:13 ET SVRA Investors have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly,
More news about: THE ROSEN LAW FIRM, P. A.
Sep 29, 2025, 14:50 ET AdventHealth West Florida Division Hospitals Among Nation's Top Performing Hospitals for Treatment of Heart Attack Patients
Negrin's wife, Bertalina Figueras Castro. Dr. Charles Lambert, medical director of the AdventHealth West Florida Division's Heart, Lung, and Vascular Institute, said Negrin's recovery is just one example of the expert, coordinated heart care AdventHealth delivers every day.
More news about: AdventHealth West Florida Division
Sep 29, 2025, 13:48 ET Vantage Market Research: Global Companion Diagnostics Market Size & Share to Surpass USD 31.75 Billion by 2035, Growing at a CAGR 11.75% | Powering Precision Medicine, Targeted Therapies and Next-Gen Drug Development
oncology pharma for lung cancer therapies. May 2025 – Illumina announces partnership with
More news about: Vantage Market Research
Sep 29, 2025, 11:00 ET Kaia Health and MedImprove Announce Collaboration to Launch Digital Pulmonary Rehabilitation Pilot for COPD Patients at ERS 2025 in Amsterdam
Health, a global leader in digital therapeutics for chronic disease management, today announced a new collaboration with MedImprove, a leading private lung rehabilitation clinic, to launch a pilot program of Kaia Breathe, its clinically validated digital pulmonary rehabilitation solution for patients
More news about: Kaia Health
Sep 29, 2025, 10:18 ET METiS Launches World's First AI-Driven Nano-Delivery Platform NanoForge
data points for model training. The company has achieved breakthrough targeted LNP delivery to eight organs and tissues in vivo, including the liver, lung, immune organs, heart, muscle, tumors, central nervous system, and gastrointestinal tract. METiS holds more than 100 granted and pending patents. It
More news about: METiS TechBio
Sep 29, 2025, 09:00 ET AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
vision, dry eyes, sensitivity to light, eye pain, eye redness, or new or worsening vision changes. Lung problems (pneumonitis). ELAHERE can cause severe or life-threatening inflammation of the lungs that may lead to death. Tell your healthcare provider
More news about: AbbVie
Sep 29, 2025, 07:00 ET CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen
pumps already found in hospitals (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the
More news about: Cytosorbents Corp
Sep 29, 2025, 07:00 ET Kedrion Biopharma Receives FDA Approval for QIVIGY® (Immune Globulin 10% IV) for treatment of Primary Humoral Immunodeficiency in Adults and confirms its plan to increase investments in the U.S. throughout its global operations.
and symptoms. Swelling of the lungs may occur following treatment. Your healthcare provider will monitor you for signs of lung damage. QIVIGY is made from human blood and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob
More news about: Kedrion Biopharma
Sep 29, 2025, 06:00 ET AllRock Bio Presents Phase 1 Data for Lead Program, ROC-101, at the ERS Congress
engagement—supporting its continued evaluation in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH). Rho kinases play an integral role in multiple aspects of fibrotic disease pathogenesis. ROCK1 and ROCK2 are
More news about: AllRock Bio
Sep 29, 2025, 03:00 ET Coreline Soft ospita un webinar con gli esperti dell'Università di Parma sulle strategie di screening del cancro ai polmoni basate sull'IA in Europa
ottenere spunti concreti e applicabili direttamente nella pratica clinica. Dopo il recente webinar con il Temple University Lung Center negli Stati Uniti lo scorso agosto, Coreline Soft sposta ora l'attenzione sull'Europa. La sessione di Parma metterà in evidenza come le tecnologie
More news about: Coreline Soft
Sep 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
"announce[ing] topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a major form of interstitial lung disease." The press release disclosed, in relevant part, that the trial had failed to meet its primary endpoint. On this news,
More news about: Pomerantz LLP
Sep 28, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA
in a Phase 3 IMPALA-2 pivotal clinical trial for the treatment of autoimmune pulmonary alveolar proteinosis ("aPAP"), a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Savara has consistently represented that, based on investments
More news about: Pomerantz LLP
Sep 28, 2025, 09:00 ET Altesa BioSciences Presents Findings Demonstrating Beneficial Effects of vapendavir for Treating Rhinovirus Infections in COPD Challenge Study
Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial slated for 2026 AMSTERDAM,
More news about: Altesa Biosciences Inc.
Sep 26, 2025, 13:50 ET The American Cancer Society and National Football League's (NFL) Crucial Catch Initiative Works to Improve Cancer Screening Rates
here. These 64 funded projects leverage various resources to expand access to breast, cervical, colorectal, lung, and prostate cancer screening in NFL markets. In 2024, Crucial Catch projects impacted 281 participating clinic sites from 33 health systems, reached
More news about: American Cancer Society
Sep 26, 2025, 09:52 ET Stephen Liu, MD, Accepts New Role as Chief of Hematology and Oncology at MedStar Georgetown University Hospital
director of Thoracic Oncology and head of Developmental Therapeutics at Georgetown Lombardi. A board-certified medical oncologist with expertise in lung cancer, he has led national and international clinical trials focused on developing novel therapies and combination treatments for advanced thoracic
More news about: MedStar Health
Sep 26, 2025, 07:35 ET Accuray Launches All-in-One Radiotherapy Solution With Advanced Capabilities Designed to Set a New Standard in Cancer Care
(SBRT) treatments and surface-guided ration therapy (SGRT), to optimize outcomes for standard radiation therapy indications including breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow irradiation. Accuray Stellar provides a unique option for accurately
More news about: Accuray Incorporated
Sep 25, 2025, 20:47 ET Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
inhibitor, Glecirasib, was approved by the National Medical Products Administration (NMPA) for second-line monotherapy in KRAS G12C mutant non-small cell lung cancer (NSCLC) and successfully launched in China. This milestone not only marked Jacobio's first commercial entry
More news about: Jacobio Pharma
Sep 25, 2025, 14:01 ET U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
survival estimates.4 About Breast CancerBreast cancer is the second most commonly diagnosed cancer worldwide (following lung cancer), according to GLOBOCAN. The estimated 2.3 million new cases indicate that close to 1 in every 4 cancers diagnosed in 2022 is breast cancer.
More news about: Eli Lilly and Company
Sep 25, 2025, 10:15 ET ELEPHAS BIOSCIENCES WELCOMES DR. JEROME GALON TO THE COMPANY'S EXPANDING SCIENTIFIC ADVISORY BOARD
M.Sc., Pathologist, Melanoma, Johns Hopkins MedicineJacob Sands, M.D., Medical Oncologist, Small Cell Lung Cancer, Dana-Farber Cancer InstituteAlan Venook, M.D., Medical Oncologist, Gastrointestinal Oncology,
More news about: Elephas